Evidence map›Paper›PMID 39086170›Full record

ArticleCardiovascular research2024

Zonation and ligand and dose dependence of sphingosine 1-phosphate receptor-1 signalling in blood and lymphatic vasculature.

Ilaria Del Gaudio, Anja Nitzsche, Kevin Boyé, Philippe Bonnin, Mathilde Poulet, Toan Q Nguyen, Ludovic Couty, Hoa T T Ha, Dat T Nguyen, Amaury Cazenave-Gassiot and 9 more

Abstract read
In one paragraph

Article in Cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Blood-borne sphingosine 1-phosphate maintains vascular resistance, blood pressure, and cardiac function in mice.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Ilaria Del GaudioUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.ORCID 0000-0001-6794-8291
Anja NitzscheUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.ORCID 0000-0003-0567-6790
Kevin BoyéUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.ORCID 0000-0002-5749-959X
Philippe BonninPhysiologie Clinique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Lariboisière, Paris, France.ORCID 0000-0003-3184-3740
Mathilde PouletUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.
Toan Q NguyenYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.ORCID 0000-0002-8015-6130
Ludovic CoutyUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.
Hoa T T HaYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.ORCID 0000-0001-5255-0870
Dat T NguyenYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.
Amaury Cazenave-GassiotYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.ORCID 0000-0002-3050-634X
Khaoula Ben AlayaUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.
Patrice ThérondService de Biochimie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
Jerold ChunNeuroscience Drug Discovery, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Markus R WenkYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.
Richard L ProiaNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-0456-1270
Daniel HenrionMitoVasc Department, Angers University, Team 2 (CarMe), Angers University Hospital (CHU of Angers), CNRS, INSERM U1083, Angers, France.ORCID 0000-0003-1094-0285
Long N NguyenYong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore.ORCID 0000-0002-9857-2239
Anne EichmannUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.ORCID 0000-0001-5563-210X
Eric CamererUniversité Paris Cité, Paris Cardiovascular Research Centre, INSERM U970, 56 Rue Leblanc, F-75015 Paris, France.ORCID 0000-0002-6271-7125

Funding

French Foundation for Medical Research DCP20171138945French National Research Agency ANR-19-CE14-0028-01Intramural Research Programs of the National Institutes of HealthLefoulon-Delalande FoundationNIDDK NIH HHS PRESTIGE-2016-3-0011Singapore Ministry of Education MOE2018-T2-1-126Singapore Ministry of Health's National Research Council NMRC/OFIRG/0066/20
6 · The paper itself

Abstract

aimsCirculating levels of sphingosine 1-phosphate (S1P), an HDL-associated ligand for the endothelial cell (EC) protective S1P receptor-1 (S1PR1), are reduced in disease states associated with endothelial dysfunction. Yet, as S1PR1 has high affinity for S1P and can be activated by ligand-independent mechanisms and EC autonomous S1P production, it is unclear if relative reductions in circulating S1P can cause endothelial dysfunction. It is also unclear how EC S1PR1 insufficiency, whether induced by deficiency in circulating ligand or by S1PR1-directed immunosuppressive therapy, affects different vascular subsets. METHODS AND

resultsWe here fine map the zonation of S1PR1 signalling in the murine blood and lymphatic vasculature, superimpose cell-type-specific and relative deficiencies in S1P production to define ligand source and dose dependence, and correlate receptor engagement to essential functions. In naïve blood vessels, despite broad expression, EC S1PR1 engagement was restricted to resistance-size arteries, lung capillaries, and a subset of high-endothelial venules (HEVs). Similar zonation was observed for albumin extravasation in EC S1PR1-deficient mice, and brain extravasation was reproduced with arterial EC-selective S1pr1 deletion. In lymphatic ECs, S1PR1 engagement was high in collecting vessels and lymph nodes and low in blind-ended capillaries that drain tissue fluids. While EC S1P production sustained S1PR1 signalling in lymphatics and HEV, haematopoietic cells provided ∼90% of plasma S1P and sustained signalling in resistance arteries and lung capillaries. S1PR1 signalling and endothelial function were both surprisingly sensitive to reductions in plasma S1P with apparent saturation around 50% of normal levels. S1PR1 engagement did not depend on sex or age but modestly increased in arteries in hypertension and diabetes. Sphingosine kinase (Sphk)-2 deficiency also increased S1PR1 engagement selectively in arteries, which could be attributed to Sphk1-dependent S1P release from perivascular macrophages.

conclusionThis study highlights vessel subtype-specific S1PR1 functions and mechanisms of engagement and supports the relevance of S1P as circulating biomarker for endothelial function.

Indexed as

Lymphatic VesselsLysophospholipidsMice, Inbred C57BLMice, KnockoutSignal TransductionSphingosineSphingosine-1-Phosphate ReceptorsAnimalsEndothelial CellsLigandsMaleLigandsLysophospholipidsS1pr1 protein, mouseSphingosinesphingosine 1-phosphateSphingosine-1-Phosphate ReceptorsEndothelial functionSignallingSphingosine 1-phosphateVascular biologyVascular integrity

Identifiers

PMID39086170
PMCPMC11587562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.